Open AccessA Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
Author(s) -
Kenji Morimoto,
Renshi Sawada,
Tadaaki Yamada,
Koichi Azuma,
Kentaro Ito,
Yasuhiro Gotô,
Hideharu Kimura,
Taishi Harada,
Shinsuke Shiotsu,
Nanako Tamiya,
Yusuke Chihara,
Takayuki Takeda,
Osamu Hiranuma,
Isao Hasegawa,
Yoshie Morimoto,
Masahiro Iwasaku,
Shinsaku Tokuda,
K. Takayama
Publication year - 2022
Publication title -
jto clinical and research reports
Language(s) - English
Resource type - Journals
ISSN - 2666-3643
DOI - 10.1016/j.jtocrr.2022.100388
Subject(s) - osimertinib , chemoimmunotherapy , medicine , lung cancer , oncology , progression free survival , chemotherapy , cancer , immunotherapy , epidermal growth factor receptor , erlotinib